Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

On location

Daratumumab-KRd Quadruplet Therapy, AHCT, and Consolidation Therapy Lead to High MRD Negativity in Newly...

Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) combination therapy, autologous hematopoietic cell transplantation (AHCT), and measurable residual disease (MRD) response-adapted consolidation led to high rates...
On location

Isatuximab Plus RVd Improves MRD Negativity Rates in Patients With Newly Diagnosed Multiple Myeloma

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) improved rates of measurable residual disease (MRD) negativity better than RVd alone in patients...
On location

GRIFFIN: Daratumumab Combination Maintains Deep Durable Response in Transplant-Eligible Myeloma

With 24 months of maintenance therapy, the combination of daratumumab and lenalidomide, bortezomib, and dexamethasone (D-RVd) continued to provide deep and durable responses in...

Melphalan Flufenamide Withdrawn From U.S. Market

Oncopeptides AB has announced its decision to withdraw melphalan flufenamide from the U.S. market after results from the phase III OCEAN study showed an...

Daratumumab Maintenance Improves PFS in Newly Diagnosed Myeloma

A two-year daratumumab maintenance regimen administered every eight weeks significantly reduced the risk of disease progression or death, compared with observation alone, in patients...

For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?

With a recent expansion in the availability of treatments for multiple myeloma (MM), several regimens have been shown to improve survival outcomes in patients...

Teclistamab Demonstrates Promising Efficacy, Safety in Relapsed/Refractory Multiple Myeloma

Treatment with a subcutaneous formulation of teclistamab, a novel bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 receptors, was well tolerated and associated...

Evaluating Venetoclax Plus Daratumumab and Dexamethasone in Relapsed/Refractory MM

Treatment with oral BCL-2 inhibitor venetoclax induced deep and durable responses in patients with relapsed or refractory multiple myeloma (MM), especially those with t(11;14)...

Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM

The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....

ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM

The U.S. Food and Drug Administration (FDA) has granted fast track designation to ALLO-605 for the treatment of adult patients with relapsed or refractory...